Literature DB >> 21182477

Comparison of status epilepticus models induced by pilocarpine and nerve agents - a systematic review of the underlying aetiology and adopted therapeutic approaches.

F R Tang1, W K Loke, E A Ling.   

Abstract

Among potential radiological, nuclear, biological and chemical weapons, cholinergic nerve agents from chemical weapons remain a realistic terrorist threat due to its combination of high lethality, demonstrated use and relative abundance of un-destroyed stockpiles in various militaries around the world. While current fielded antidotes are able to mitigate acute poisoning, effective neuroprotection in the field remains a challenge amongst subjects with established status epilepticus following nerve agent intoxication. Due to ethical, safety and surety issues, extensive preclinical and clinical research on cholinergic nerve agents is not possible. This may have been a contributory factor for the slow progress in uncovering new neuroprotectants for nerve agent casualties with established status epilepticus. To overcome this challenge, comparative research with surrogate chemicals that produce similar hypercholinergic toxicity but with less security concerns would be a useful approach forward. In this paper, we will systemically compare the mechanism of seizure generation, propagation and the subsequent clinical, hematologic, and metabolic, biochemical, neuroinflammatory changes and current therapeutic approaches reported in pilocarpine, soman, and sarin models of seizures. This review will be an important first step in closing this knowledge gap among different closely related models of seizures and neurotoxicity. Hopefully, it will spur further efforts in using surrogate cholinergic models by the wider scientific community to expedite the development of a new generation of antidotes that are better able to protect against delayed neurological effects inflicted by nerve agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21182477     DOI: 10.2174/092986711794927720

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  7 in total

1.  The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala.

Authors:  Steven L Miller; Vassiliki Aroniadou-Anderjaska; Volodymyr I Pidoplichko; Taiza H Figueiredo; James P Apland; Jishnu K S Krishnan; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2016-10-31       Impact factor: 4.030

2.  Oxidative Stress Contributes to Status Epilepticus Associated Mortality.

Authors:  Jennifer N Pearson-Smith; Li-Ping Liang; Shane D Rowley; Brian J Day; Manisha Patel
Journal:  Neurochem Res       Date:  2017-05-02       Impact factor: 3.996

Review 3.  Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy.

Authors:  Aynara C Wulsin; Matia B Solomon; Michael D Privitera; Steve C Danzer; James P Herman
Journal:  Physiol Behav       Date:  2016-05-16

Review 4.  Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic?

Authors:  G Curia; C Lucchi; J Vinet; F Gualtieri; C Marinelli; A Torsello; L Costantino; G Biagini
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Blood-Brain Barrier Leakage during Early Epileptogenesis Is Associated with Rapid Remodeling of the Neurovascular Unit.

Authors:  Marion Bankstahl; Heike Breuer; Ina Leiter; Martin Märkel; Pablo Bascuñana; Dominik Michalski; Frank M Bengel; Wolfgang Löscher; Martin Meier; Jens P Bankstahl; Wolfgang Härtig
Journal:  eNeuro       Date:  2018-05-30

6.  Advances in toxicology and medical treatment of chemical warfare nerve agents.

Authors:  Mohammd Moshiri; Emadodin Darchini-Maragheh; Mahdi Balali-Mood
Journal:  Daru       Date:  2012-11-28       Impact factor: 3.117

7.  Recent advances in the treatment of organophosphorous poisonings.

Authors:  Mahdi Balali-Mood; Hamidreza Saber
Journal:  Iran J Med Sci       Date:  2012-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.